Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 241-245

  Markman, Maurie ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Chemotherapy; Optimal residual disease; Ovarian cancer

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DNA REPAIR; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; GYNECOLOGIC CANCER; HUMAN; LONG TERM SURVIVAL; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84885323407     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.029     Document Type: Review

References (26)

1. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10): 943-53.
2. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery during an initial time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy. Gynecol Oncol 2012;124(1): 10-4.
3. Markman M. Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol 2006;10: 229-30.
4. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101: 1642-9.
5. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29): 4699-707.
6. Aghajanian C, Blank SW, Goff BA, et al. A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17): 2039-45.
7. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1): 1-6.
8. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin/cyclophosphamide as first-line treatment of ovarian cancer. J Natl Cancer Inst 2000;92(9): 699-708.
9. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17): 3194-200.
10. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17): 1320-9.
11. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003;4: 277-83.
12. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 2009;374: 1331-8.
13. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96: 1682-91.
14. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006;24: 988-94.
15. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335: 1950-5.
16. MarkmanM, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19: 1001-7.
17. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. 2006;354(1): 34-43.
18. NCI Clinical Announcement. http://ctep.cancer.gov/highlights/20060105- ovarian.htm.
19. Tewari D, Java J, Salani R, et al. Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study. Proceedings 44th Annual Meeting of Society of Gynecologic Oncology, Los Angeles, CA; 2013 (Abstract 6; S6).
20. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 Expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study.Br J Cancer 2013 [in press].
21. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl Med 2011;365(26): 2473-83.
22. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26): 2484-96.
23. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.J Clin Oncol 2012;30 [Suppl.; abst LBA 5002].
24. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomized phase 3 trial. Lancet Oncol 2013;14: 29-37.
25. Randall L, Burger R, Nguyen H, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Proceedings 44th Annual Meeting of Society of Gynecologic Oncology, Los Angeles, CA; 2013 (Abstract 80; S34).
26. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21(13): 2460-5.